Drug intelligence / Profile preview

SLV337

Development stage: Phase 1
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

SLV337 is an investigational small molecule drug that was developed for the treatment of type 2 diabetes. It was studied in clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with type 2 diabetes, particularly those on metformin monotherapy. The drug was administered orally. As of September 2015, it was no longer listed on the AbbVie (formerly Abbott Laboratories) pipeline and appears to have been discontinued from active development[1][2][4][5]. The precise mechanism of action for SLV337 has not been publicly disclosed[4].

Beyond the preview

Go deeper on SLV337.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLV337.

Explore the full profile